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Abstract Colorectal carcinoma is, through to its high rate
of liver metastasis (mCRC), the second most cause of
cancer death worldwide. Tumor resection represents the
only potential cure. In cases of unresectable disease sys-
temic chemotherapy (sCHT) remains the therapy of choice.
Modern sCHT regimens including biological agents can
induce tumor response that leads to curative surgery of
initially unresectable mCRC. However, liver-directed
therapy via hepatic arterial infusion (HAI) may produce
higher response rates than sCHT. Herein we studied whe-
ther a HAI of cetuximab (CE) plus bevacizumab (BE) with
or without oxaliplatin (OX) can inhibit tumor growth in a
rat model. WAG/Rij rats underwent subcapsular hepatic
tumor implantation. After 10 days animals received either
HAI or sCHT of CE plus BE, OX or all three drugs. Saline-
treated animals served as controls. Tumor growth was
estimated at day 10 and 13. On day 13 liver and tumor
tissue was studied histologically and immunohistochemi-
cally. In controls the tumors grew about 50 %. OX alone
was not capable of inhibiting tumor growth. In contrast, CE
plus BE given as HAI significantly reduced tumor growth
compared to sCHT (p \ 0.05). HAI of CE plus BE com-
bined with OX yielded an even more pronounced inhibition
of tumor growth. Immunohistochemistry revealed a
decreased tumor cell proliferation and tumor vasculariza-
tion. The present study demonstrates that HAI of CE plus
BE is effective to inhibit tumor growth. This effect is even
more pronounced in combination with OX. Systemic
application of these agents cannot achieve comparable
effects.
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Introduction
Colorectal carcinoma has a rising incidence and is the second
most cause of cancer related death worldwide [1, 2]. About
50 % of patients develop metastatic disease, whereby the
liver remains the most common site of metastasis. These
patients have a poor prognosis demonstrated by a 5-year
survival rate in the range of 5–8 %. The only potential cure is
complete resection of the hepatic tumor burden [3]. Unfor-
tunately, a great number of patients suffer from unresectable
disease. In these patients the main goal is to induce tumor
response by systemic chemotherapy which can lead to
curative surgery of initially unresectable metastases.
During the last years, the development of new cytotoxic
drugs and regimens as well as biological targeted agents
like cetuximab (CE) or bevacizumab (BE) has improved
the survival outcome of patients with unresectable disease
[3]. Cetuximab is a monoclonal antibody directed against
the ligand binding domain of the epidermal growth factor
receptor (EGF-R). Bevacizumab is a monoclonal antibody
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directed against the vascular endothelial growth factor
(VEGF). The use of these antibodies in modern sCHT
regimens has improved the 2-year survival rate, however, it
still does not exceed 40 %. Of interest, the analysis of the
5-year survival rate could not show a benefit of the survival
outcome [3, 4].
It is well known that liver-directed chemotherapy, which
is achieved by hepatic arterial infusion, yields reproducibly
higher response rates compared to sCHT both in preclinical
and clinical settings [2, 5]. However, the overall value of
HAI remains unclear [6]. Therefore, it has been suggested
to evaluate the effect of a HAI especially with the delivery
of novel cancer agents or drug combinations in further
studies [7]. Accordingly, we herein studied whether a HAI
of cetuximab plus bevacizumab (CE ? BE) alone or in
combination with oxaliplatin (OX) is more effective than




For the experiments we used 48 male WAG/Rij rats with a
body weight of 248.3 ± 5.5 g (mean ± standard error of
the mean (SEM)). Animals were kept in a temperature- and
humidity-controlled 12 h light/dark cycle environment
with free access to water and standard laboratory chow
(Altromin, Lage, Germany).
Experimental protocol
All experiments were approved by the local governmental
ethic committee. Animals were randomized to eight groups
(n = 6 each), whereby four groups of animals underwent
HAI and four groups underwent sCHT. 10 days after tumor
cell implantation relaparotomy was performed and animals
received either (CE ? BE), (OX) or all three drugs (CE ?
BE ? OX) via HAI or sCHT. Sham animals received a
comparable amount of 0.9 % saline solution (Braun,
Melsungen, Germany) and served as controls (HAI sham,
sCHT sham). Prior to the treatment the tumor volume was
estimated by three-dimensional ultrasound imaging. Three
days later animals underwent relaparotomy and reexami-
nation of the tumor volume by three-dimensional ultra-
sound imaging. Finally, animals were sacrificed and tissue
was sampled for histological and immunohistochemical
analysis. Body weight was measured for determination of
weight reduction on the day of tumor implantation as well
as at the end of the experiments.
Tumor cell implantation
Under ether anesthesia a median laparotomy was per-
formed. Induction of colorectal liver metastases was
achieved by injection of 5 9 105 cells of the syngeneic
CC531 rat colon carcinoma cell line (CLS, Heidelberg,
Germany) under the capsule of the lower surface of the left
liver lobe using a 27G needle (Omnican F, B. Braun,
Melsungen, Germany). Laparotomy was closed with a one-
layer running 4-0 PDS suture (Ethicon/Johnson & Johnson
Medical GmbH, Norderstedt, Germany).
Drugs
Cetuximab was administered in a dose of 114 mg/m2, BE in a
dose of 5 mg/kg body weight and OX in a dose of 77 mg/m2.
For the calculation of the body surface area we used ‘‘Meeh’s
formula’’, which reads as follows: A = K 9 W2/3. Hereby, A
represents the body surface area, K an animal specific constant,
which was set to 9.83 and W the individual body weight [8].
Drug application via HAI and sCHT
On day 10 after tumor cell implantation, animals were
relaparotomized under ether anaesthesia. For the HAI the
gastroduodenal artery was cannulated (ID 0.28 mm,
Portex, Hythe, UK), whereby the tip of the catheter was
positioned at the entrance to the common hepatic artery.
During the HAI the artery showed orthograde blood flow
with no signs of occlusion. After HAI the catheter was
removed and the gastroduodenal artery was ligated. For
sCHT the subhepatic vena cava was punctured with a 23G
needle (Troge Medical GmbH, Hamburg, Germany)
according to previously published standards [5].
Three dimensional ultrasound imaging
Using the 40 MHz ultrasound probe of the Vevo 770 high-
resolution imaging system (VisualSonics, Inc., Toronto,
Ontario, Canada) the tumor volume was measured on day
10 and 13. The 40 MHz ultrasound probe was attached to a
stepping motor that moved the probe over the surface of the
left liver lobe. Thus, parallel two dimensional images were
acquired in intervals of 50 lm. The tumor dimension was
outlined off-line on every 200 lm of the two dimensional
images. With this data, the integrated software of the Vevo
770 high-resolution imaging system calculated a polygonal
three dimensional image and the tumor volume (Fig. 1a–d).
Sampling and assays
Venous blood samples were taken at day 10 and 13 via puncture
of the subhepatic vena cava. Aspartate aminotransferase
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(ASAT), alanine aminotransferase (ALAT) and glutamate
dehydrogenase (GLDH) serum activities were analyzed using
routine spectrophotometric techniques and served as indicators
of hepatocellular injury. White blood cell count was determined
with the use of a cell counter.
Histology
Tissue samples of the liver were fixed in 4 % phosphate-
buffered formalin and then embedded in paraffin. Sections
of 5 lm stained with hematoxylin-eosin (HE) were used to
perform analyses of hepatocellular vacuolization, venular
endothelial detachment and venular fibrin clotting. Hepa-
tocellular vacuolization was estimated using a semiquan-
titative score (0 = none; 1 = mild; 2 = moderate and
3 = severe). Venular endothelial detachment was analyzed
by counting the number of venules with detachment of
endothelial lining cells and documented in percent of all
venules analyzed. Fibrin clotting was determined by
counting the number of venules with fibrin clots and doc-
umented in percent of all venules analyzed.
Immunohistochemical analysis
Cleaved caspase-3 (cysteine-aspartic proteases) served as
an indicator of apoptotic cell death. Sections of 5 lm of
tumor-bearing specimens were incubated overnight at
room temperature with a rabbit polyclonal anti-cleaved
caspase-3 antibody (1:50, Cell Signaling Technology,
Frankfurt, Germany). As secondary antibody a peroxidase-
conjugated goat-anti-rabbit-IgG antibody (1:100, Dianova,
Hamburg, Germany) was used. 3.30 diaminobenzidine
served as chromogen. Counterstaining was performed with
hemalaun. Per specimen 25 high-power-fields (HPF) were
analyzed and positively stained cells were counted and
given as number per HPF.
For the estimation of cell proliferation PCNA (prolif-
erating cell nuclear antigen) was analyzed. Therefore,
paraffin-embedded specimens sectioned in 5 lm intervals
were incubated for 18 h at 4 C with a mouse monoclonal
anti-PCNA antibody (1:50; Dako, Hamburg, Germany).
For development of PCNA, a peroxidase-conjugated goat
anti-mouse IgG antibody (1:100; Dianova) was incubated
for 30 min. 3.30 diaminobenzidine served as chromogen.
Hemalaun was used for counterstaining. PCNA-positive
cells were analyzed using the following score: 0 B 1 %,
1 = 1–10 %, 2 = 10–30 %, 3 = 30–50 %, 4 C 50 % of
PCNA-positive cells.
PECAM-1 (platelet-endothelial cell adhesion molecule-
1) was used as an indicator for vascularization. The immu-
nohistochemical detection of PECAM-1 expression was
achieved using a primary mouse-anti-rat antibody (1:500;
clone TLD-3 A12, Serotec, Du¨sseldorf, Germany) and a
secondary peroxidase-conjugated goat-anti-mouse antibody
(Dianova). PECAM-1-positive blood vessels were counted
in 25 HPF per section and are given as number per HPF.
Statistical analysis
After analysis of normal distribution and homogeneity of
variance of the data, differences between the four HAI and
the four sCHT groups were calculated separately by one-way
analysis of variance (ANOVA) followed by an adequate post
hoc-test (Student–Newman–Keuls test), including the cor-
rection of the alpha-error according to Bonferroni proba-
bilities to compensate for multiple comparisons. The
pairwise comparison between the HAI groups and the
respective sCHT groups was performed by Student’s t test
including a correction of the alpha-error according to Bon-
ferroni–Holm. Statistical significance was set at p \ 0.05
and changed according to the Bonferroni–Holm procedure.
All values are expressed as mean ±Standard error of the
mean SEM.
Results
Metastatic tumor establishment, general health
conditions and body weight
10 days after tumor implantation all animals showed a
solitary tumor of 5–10 mm in diameter in the left liver
lobe. There were no signs of extrahepatic disease. Animals
were not affected by the tumor as indicated by normal
feeding and cleaning habits.
Analysis of the body weight of the sham groups dem-
onstrated a slight but significant difference between HAI-
and sCHT-treated animals between day 0 and 13, whereas
between the other groups no significant differences were
found (Table 1). Of interest, almost all groups receiving
drug application showed a significant difference compared
Table 1 Change of body weight (%) from day 0 to 13
Group HAI sCHT
Sham -2.1 ± 0.4# ?8.3 ± 1.2
CE ? BE -1.4 ± 1.2 -3.4 ± 1.0*
CE ? BE ? OX -6.8 ± 0.8* -7.8 ± 1.9*
OX -6.8 ± 1.8* -0.9 ± 3.7*
Change of body weight from day 0 to 13 (given in percent). Animals
were treated either with hepatic arterial infusion (HAI) or systemic
application (sCHT) of saline (sham), cetuximab plus bevacizumab
(CE ? BE), the combination of cetuximab, bevacizumab and oxa-
liplatin (CE ? BE ? OX) or oxaliplatin alone (OX). Data are given
as mean ± SEM
* p \ 0.05 versus sham; # p \ 0.05 versus corresponding sCHT
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to the corresponding sham controls, irrespective of whether
a HAI or sCHT was performed (Table 1).
Metastatic tumor growth
Ultrasound analysis in both HAI- and sCHT-sham animals
revealed an almost 50 % increase of tumor volume from
day 10 to 13 (Fig. 1). HAI or sCHT of OX alone induced
only a slight but not significant decrease of tumor growth
compared to sham controls. Of interest, HAI of the
monoclonal antibodies (HAI CE ? BE) induced a greater
inhibition of tumor growth during the three-day period.
Moreover, the combination of the monoclonal antibodies
with OX given via HAI (HAI CE ? BE ? OX) not only
inhibited tumor growth, but significantly reduced the tumor
size (Fig. 1). In contrast, systemic application (sCHT) of
CE ? BE and CE ? BE ? OX was not capable of
affecting the tumor growth (Fig. 1).
Tumor cell proliferation
Immunohistochemical analysis of tumor cell proliferation
revealed up to 50 % PCNA-positive cells in sham controls
of HAI- and sCHT-treated animals (Fig. 2). Application of
OX alone showed almost similar results (Fig. 2). In con-
trast, CE ? BE but in particular the combination of
CE ? BE with OX (CE ? BE ? OX) significantly low-
ered the number of proliferating tumor cells compared to
sham controls. This effect was most pronounced in animals
treated with HAI of CE ? BE ? OX (Fig. 2).
Apoptotic tumor cell death
Analysis of cleaved caspase-3-positive cells showed a
slight but not significant increase of apoptotic cell death in
the tumor tissue after CE ? BE and also after OX alone
compared to sham controls (Fig. 3). However, the combi-
nation of all three agents (CE ? BE ? OX) when given
via HAI significantly increased the number of apoptotic
cells by more than three-fold compared to HAI sham
controls. In contrast, the number of apoptotic cells after
sCHT CE ? BE ? OX was not significantly increased
compared to sCHT sham (Fig. 3).
Tumor vascularization
HAI of CE ? BE, CE ? BE ? OX and OX alone signifi-
cantly reduced the number of PECAM-1-positive blood





































Fig. 1 Panels a–d display the different phases of the three dimen-
sional ultrasound imaging of the tumor (a Ultrasound image of the
tumor bearing left liver lobe. b Off-line outlining of the tumor (red
line), c Three dimensional cube, d Three dimensional cube with
polygonal image of the tumor). The Tumor volume was measured on
day 13 in percent of the volume measured on day 10 after HAI (e) and
sCHT (f) of saline (sham), cetuximab plus bevacizumab (CE ? BE)
and oxaliplatin (OX) or the combination of all three drugs
(CE ? BE ? OX). Data are given as mean ± SEM; *p \ 0.05
versus sham; #p \ 0.05 versus corresponding sCHT
c
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vessels by *50 % compared to sham controls. The reduc-
tion of PECAM-1-positive blood vessels was found most
pronounced in animals receiving CE ? BE ? OX (Fig. 4).
Of interest, although sCHT of CE ? BE, CE ? BE ? OX
and OX alone were capable of decreasing the number of
blood vessels, this effect was less pronounced compared to
that observed in HAI-treated animals (Fig. 4).
Histomorphological analysis
Vacuolization of the hepatocytes was overall moderate,
although it was most pronounced after sCHT of OX (data







































Fig. 2 Immunohistochemical sections of proliferating nuclear cell
antigen (PCNA) expression in the tumor tissue (a and b). The PCNA-
positive cells are stained brown (a HAI sham group, b HAI
CE ? BE ? OX). Panels c and d show the data of the immunohis-
tochemical analysis of PCNA (given as index: 0B 1 %, 1 = 1–10 %,
2 = 10–30 %, 3 = 30–50 %, 4 C 50 % of PCNA-positive cells) in
the tumor of animals undergoing HAI (c) or sCHT (d) of cetuximab
plus bevacizumab (CE ? BE), oxaliplatin (OX) or the combination of
all three drugs (CE ? BE ? OX). Animals undergoing HAI or
systemic application with saline served as controls (sham). Data are
given as mean ± SEM; *p \ 0.05 versus sham. 9200 magnification












































Fig. 3 Immunohistochemical sections of cleaved caspase-3 as an
indicator of apoptotic cell death (a and b). Apoptotic cells are stained
brown (a sCHT CE ? BE ? OX, b HAI CE ? BE ? OX). Panels
c and d display the quantitative analysis of cleaved caspase-3-positive
cells in the tumor (given as number per HPF) of animals undergoing
HAI (c) or sCHT (d) of cetuximab plus bevacizumab (CE ? BE),
oxaliplatin (OX) or the combination of all three drugs (CE ?
BE ? OX). Animals undergoing HAI or systemic application of
saline served as controls (sham). Data are given as mean ± SEM;
*p \ 0.05 versus sham. 9200 magnification
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not shown). Endothelial detachment or vascular fibrin
clotting was overall negligible (data not shown). Thus,
histological analysis could not reveal significant differ-
ences between HAI or sCHT treatment.
Blood cell analysis
Analysis of white blood cell count showed a decrease of
leukocytes from day 10 to 13 when OX was given alone or
in combination with the monoclonal antibodies. The
decrease of the number of white blood cells was found
most pronounced after systemic application of OX (Fig. 5).
Application of the antibodies only, regardless whether
systemically or via HAI, did not affect white blood cell
count.
Analysis of liver enzymes
Analysis of the liver enzymes ASAT and ALAT as indi-
cators of hepatocellular injury did not show any relevant
differences between HAI or sCHT groups. Of interest,













































Fig. 5 Panels a and b show the analysis of white blood cell count of
animals undergoing HAI (a) or sCHT (b) of cetuximab plus
bevacizumab (CE ? BE), oxaliplatin (OX) or the combination of
all three drugs (CE ? BE ? OX). Animals undergoing HAI or
systemic application of saline served as controls (sham). Data are
given as mean ± SEM; *p \ 0.05 versus sham; #p \ 0.05 versus
corresponding sCHT


























































Fig. 4 Immunohistochemical sections of PECAM-1-positive blood
vessels of the tumor tissue (a and b). PECAM-1-positive blood vessels
are stained brown (a HAI sham, b HAI CE ? BE ? OX). Panels c and
d show the quantitative analysis of PECAM-1-positive blood vessels in
the tumor (given as number per HPF) of animals undergoing HAI (c) or
sCHT (d) of cetuximab plus bevacizumab (CE ? BE), oxaliplatin (OX)
or the combination of all three drugs (CE ? BE ? OX). Animals
undergoing HAI or systemic application of saline served as controls
(sham). Data are given as mean ± SEM; *p\0.05 versus sham;
#p\0.05 versus corresponding sCHT. 9400 magnification
452 Clin Exp Metastasis (2013) 30:447–455
123
GLDH as an indicator of mitochondrial damage was
slightly increased after HAI of CE ? BE ? OX and OX
alone compared to the respective sCHT groups (data not
shown).
Discussion
The major finding of the present study is that a HAI of the
monoclonal antibodies CE and BE is effective to inhibit
tumor growth in a colorectal rat liver metastasis model.
Moreover, the combination of CE and BE with OX given
via HAI not only inhibited tumor growth, but was even
capable of decreasing the tumor size. Of interest, these
effects could not be observed when the drugs were applied
as sCHT.
Colorectal cancer has a rising incidence worldwide and
is, today, the leading cause of cancer death in Germany
with an incidence of *60,000 per year [1, 9]. The prog-
nosis is mostly determined by its high rate of liver
metastases. About 20 % of patients show synchronous
hepatic metastases and 20–30 % develop metachronous
disease [9]. However, due to unresectable disease or lim-
iting comorbidities liver resection is only feasible in less
than 25 % of the patients [10]. Because liver resection
represents the only curative approach, therapeutic strate-
gies are mandatory to primary downsize the tumor and
make surgery feasible in as many patients as possible.
Systemic chemotherapy (sCHT) remains the therapy of
choice in the treatment of unresectable mCRC. The most
common algorithms comprise 5-fluorouracil plus leucovo-
rin in combination with irinotecan or OX (FOLFIRI and
FOLFOX). These are reported to enable a resection rate of
9–40 % among patients with initially unresectable disease
[11, 12]. The integration of targeted agents, such as the
monoclonal antibodies CE and BE, has led to a further
improvement of the patients outcome [13]. Cetuximab is
known to be capable of increasing the resectability rate in
patients with primary unresectable disease refractory to
conventional first-line therapy [14]. In several clinical
studies BE has also been proven to increase the resect-
ability rate [15–17]. Whether the combination of CE and
BE can lead to a further improvement remains to be
determined and is part of current research [18, 19].
However, beside the contents of the chemotherapy
regimens, today, there is an ongoing discussion whether the
efficacy of chemotherapy can be augmented by changing
the route of delivery. Hepatic arterial infusion as a liver-
directed loco-regional drug application is capable of
increasing the local concentration of a specific tumoricidal
agent compared to sCHT and may thus increase its anti-
tumor activity [20]. Although higher response rates were
reported using HAI with different drugs, this did not
translate into a significant survival benefit for the patients
[7]. Thus, current reviews came to the conclusion that the
value of HAI needs to be newly investigated with the use of
novel agents like CE, BE and OX [2, 6, 7].
In the present study the systemic application of CE and
BE did not inhibit tumor growth of CC531 colorectal rat
liver metastases. In contrast, the liver-directed therapy of
these agents led to a significant inhibition of tumor growth.
The major anti-tumor effect of CE and BE is related to the
inhibition of angiogenesis. CE is a monoclonal human/
murine chimeric antibody against the EGF-R, which is
overexpressed in colorectal cancer [21–23]. Deregulation
of EGF-R decreases tumor proliferation, angiogenesis and
resistance to apoptosis [24].
BE is a recombinant humanized monoclonal antibody,
targeting the VEGF by binding its soluble form, which pre-
vents the ligand from binding to the VEGF receptor (VEGF-
R) [25]. The VEGF/VEGF-R system plays a major role in
angiogenesis and, especially, metastatic colorectal cancer
has been shown to involve VEGF expression [26]. The
tumoricidal effects of BE were shown in several preclinical
studies, describing effective inhibition of angiogenesis,
induction of apoptosis and reduction of proliferation [27–
35]. As single agents, as well as in combination with OX,
both CE and BE already showed their anti-tumor activity
given as HAI in a rodent model of liver metastases [5,
unpublished data].
However, due to the different modes of action it may be
speculated that CE and BE together provide an additive
anti-tumor effect. The evaluation of the short-term effects
in the present study demonstrates that a single HAI of the
drug combination CE plus BE decreases tumor cell pro-
liferation and increases the rate of apoptotic cell death in
the tumor tissue. Moreover, the analysis of PECAM-1
expression revealed a reduction of the number of tumor
blood vessels by *50 % after HAI of CE plus BE. In
accordance, a considerable inhibition of tumor growth was
detected. These effects were even more pronounced when
CE ? BE were combined with OX.
Oxaliplatin, a well known cytostatic drug, is a diami-
nocyclohexane platinum, which provides a large spectrum
of anti-cancer activity [36–43]. In a preclinical study
Dzodic et al. [36] found a significant pharmacokinetic
advantage when OX was given as HAI compared to sys-
temic i.v. administration. Clinical studies have underlined
this finding, showing promising results without major tox-
icity in the treatment of colorectal liver metastases with
OX-based HAI therapy [44–46]. Accordingly, in the present
study we detected an increased anti-tumor effect when OX
was added to CE ? BE. This is illustrated by the fact that
the anti-proliferative, pro-apoptotic and anti-angiogenic
effects were found most pronounced after HAI of
CE ? BE ? OX. As a result, this therapeutic regime not
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only inhibited tumor growth but additionally induced tumor
destruction.
Accordingly, we assume that the mechanisms of action
inhibiting tumor growth after HAI of CE ? BE ? OX are
multifactorial, including the anti-angiogenic properties of
the drugs, but also direct anti-proliferative and pro-apop-
totic actions.
This view is in line with in vitro data from others. Balin-
Gauthier and coworkers [47] showed that CE potentiates the
OX-mediated cytotoxic effect as a result of inhibition of
nucleotide excision repair and also DNA replication initia-
tion. Comparable results were found by Fan et al. for anti-
VEGF-therapies. The authors showed that the exposure of
human colorectal cancer cells to OX led to a marked
induction of VEGF and concluded, that the neutralization of
pro-survival responses with anti-VEGF therapy might
explain some of the beneficial effects of anti-VEGF therapy
when added to chemotherapy [48].
Of interest, it is known that the drug combination of
CE ? BE ? OX is not necessarily associated with greater
side effects when compared with those observed after
single application of the drugs [49]. In line with this, we
did not observe toxic side effects in the HAI-treated ani-
mals and sCHT controls during the 3 day follow up period
in the present study.
Taken together, our short-term analysis in a rodent
model of colorectal liver metastases demonstrates that HAI
of CE ? BE ? OX is more effective to inhibit tumor
growth compared to sCHT of these drugs.
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